High plasma retinol binding protein 4 (RBP4) is associated with systemic inflammation independently of low RBP4 adipose expression and is normalized by transplantation in nonobese, nondiabetic patients with chronic kidney disease

Barazzoni, Rocco; Zanetti, Michela; Semolic, A.; Pirulli, A.; Cattin, Maria Rosa; Biolo, Gianni; Bosutti, Alessandra; Panzetta, Giovanni; Bernardi, Annamaria; Guarnieri, Gianfranco

doi:10.1111/j.1365-2265.2011.03990.x

Cited by 16 publications

(14 citation statements)

References 29 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we speculate that RBP4 is not a biomarker of LVD but that this adipokine may simply accumulate in the circulation in advanced HF, as a consequence of kidney function deterioration clinically manifested by cardiorenal syndrome. This hypothesis is supported by studies reporting elevated plasma RBP4 levels in CKD [27][28][29], and its normalization after kidney transplantation [30,31], as well as the results of the multivariate regression analysis in the presented study. Further evidence can be seen with normal RBP4 levels in patients with Table 3.…”

Section: Discussionsupporting

confidence: 77%

“…A study performed in normal-weight, nondiabetic CKD subjects proved that RBP4 plasma elevation could be an effect of passive accumulation of transthyretin (TTR) -the protein that carries RBP4 bound to retinol in circulation, and prevents its filtration in the kidneys [30]. It has been shown that fenretinide (a synthetic retinoid that disrupts binding of RBP4 to TTR) enhances renal excretion and leads to decreased RBP4 concentration levels in mice [31].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Level of Retinol-Binding Protein 4, N-Terminal proBNP and Renal Function in Older Patients Hospitalized for Heart Failure

et al. 2018

View full text Add to dashboard Cite

Background/Aim: Elevated plasma concentration of retinol-binding protein 4 (RBP4) has recently emerged as a potential new risk factor for cardiovascular diseases, including hypertension (HT) and coronary artery disease (CAD). Limited data suggest that RBP4 promotes inflammatory damage to cardiomyocytes and participates in the development of heart failure (HF). This study aimed to analyze the relationship between concentrations of plasma RBP4 and serum N-terminal proBNP (NT-proBNP), a powerful biomarker of left ventricle dysfunction, in the older Polish population. Methods: The study sample consisted of 2,826 (1,487 men) participants of the PolSenior study, aged 65 years and older, including a subgroup hospitalized for HF (n = 282). In all subjects, plasma concentrations of RBP4, interleukin-6 (IL-6), serum level of NT-proBNP, and hs-CRP were measured. Additionally, BMI, estimated glomerular filtration rate (eGFR), and HOMA-IR were calculated. The prevalence of HT, CAD, atrial fibrillation (AF), and medication were considered as potential confounders. Results: Similar RBP4 levels were found in subjects with NT-proBNP < 125 and ≥125 ng/mL, with and without AF, and in the subgroups hospitalized for HF with and without AF. Regression analysis revealed no association between log₁₀(NT-proBNP) and log₁₀(RBP4). Plasma levels of RBP4 were increased by HT occurrence and diuretic therapy, while diminished with regard to female gender, age, eGFR values, AF, and IL-6 levels. Conclusion: Our results show that RBP4 is affected by GFR but cannot be considered as an independent biomarker of heart muscle dysfunction.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Plasma Level of Retinol-Binding Protein 4, N-Terminal proBNP and Renal Function in Older Patients Hospitalized for Heart Failure

et al. 2018

View full text Add to dashboard Cite

show abstract

“…RBP-4 levels were significantly decreased following weight loss after a bariatric surgery (Haider et al, 2007; Gomez-Ambrosi et al, 2008; Tschoner et al, 2008). Barazzoni et al (2011) showed that high plasma RBP-4 levels was correlated with high systemic inflammatory responses in non-obese, non-diabetic patients with chronic kidney disease (But the correlation was independent of RBP-4 expression in adipose tissue. More studies are required to investigate the roles of RBP-4 in inflammation.…”

Section: The Changes Of Novel Adipokines After Bariatric Surgery and mentioning

confidence: 99%

Effects of Bariatric Surgery on Adipokine-Induced Inflammation and Insulin Resistance

Göktaş¹,

Moustaid‐Moussa²,

Shen³

et al. 2013

Front. Endocrinol.

View full text Add to dashboard Cite

Over a third of the US population is obese and at high risk for developing type 2 diabetes, insulin resistance, and other metabolic disorders. Obesity is considered a chronic low-grade inflammatory condition that is primarily attributed to expansion and inflammation of adipose tissues. Indeed, adipocytes produce and secrete numerous proinflammatory and anti-inflammatory cytokines known as adipokines. When the balance of these adipokines is shifted toward higher production of proinflammatory factors, local inflammation within adipose tissues and subsequently systemic inflammation occur. These adipokines including leptin, visfatin, resistin, apelin, vaspin, and retinol binding protein-4 can regulate inflammatory responses and contribute to the pathogenesis of diabetes. These effects are mediated by key inflammatory signaling molecules including activated serine kinases such as c-Jun N-terminal kinase and serine kinases inhibitor κB kinase and insulin signaling molecules including insulin receptor substrates, protein kinase B (PKB, also known as Akt), and nuclear factor kappa B. Bariatric surgery can decrease body weight and improve insulin resistance in morbidly obese subjects. However, despite reports suggesting reduced inflammation and weight-independent effects of bariatric surgery on glucose metabolism, mechanisms behind such improvements are not yet well understood. This review article focuses on some of these novel adipokines and discusses their changes after bariatric surgery and their relationship to insulin resistance, fat mass, inflammation, and glucose homeostasis.

show abstract

“…Nonetheless, positive associations were documented for circulating RBP4 or RBP4 expression levels with established CVD risk factors, including metabolic syndrome, 6, 7, 15 overall/central obesity, 15–18 dyslipidemia, 3, 5, 6, 11, 15, 18, 19 inflammatory markers, 20–22 and hypertension. 18, 23 Moreover, RBP4 levels have been positively associated with carotid intima-media thickness 23, 24 and prevalent CVD events.…”

mentioning

confidence: 99%

Plasma Retinol-Binding Protein 4 (RBP4) Levels and Risk of Coronary Heart Disease

et al. 2013

View full text Add to dashboard Cite

Background Retinol-binding protein 4 (RBP4) may play an important role in the etiology of insulin resistance and metabolic syndrome. Few prospective data are available on the relationship between RBP4 and coronary heart disease (CHD). Further, previous studies did not distinguish among full-length and truncated forms of RBP4 that might have various biological activities. Methods and Results We measured plasma levels of full-length and several C-terminally truncated sub-fractions of RBP4 among 468 women who developed CHD and 472 matched controls in the Nurses’ Health Study cohort during 16 years of follow-up (1990–2006). We observed a temporal variation in the association of full-length RBP4 levels with CHD risk (P=0.04 for testing proportional hazard assumption). In the first 8 years of follow-up, after multivariate adjustment for covariates, the odds ratio (OR) of CHD risk comparing extreme quartiles of full-length RBP4 levels was 3.56 (95% CI: 1.21, 10.51; Ptrend=0.003), whereas this association was 0.77 (0.38, 1.56; Ptrend=0.44) in the follow-up period of 9–16 years. Results were similar for total RBP4 levels (summed levels of all RBP4 isoforms). Levels of the primary truncated isoform, RBP4-L, were not associated with CHD risk in any follow-up period; the ORs (95% CI) for extreme quartiles were 1.29 (0.50, 3.32) and 1.20 (0.64, 2.26) in the first and second 8 years of follow-up, respectively. Conclusions In this cohort of women, higher circulating full-length and total RBP4 levels were associated with increased risk of CHD in a time-dependent fashion. Additional data are warranted to confirm the current findings.

show abstract

High plasma retinol binding protein 4 (RBP4) is associated with systemic inflammation independently of low RBP4 adipose expression and is normalized by transplantation in nonobese, nondiabetic patients with chronic kidney disease

Cited by 16 publications

References 29 publications

Plasma Level of Retinol-Binding Protein 4, N-Terminal proBNP and Renal Function in Older Patients Hospitalized for Heart Failure

Plasma Level of Retinol-Binding Protein 4, N-Terminal proBNP and Renal Function in Older Patients Hospitalized for Heart Failure

Effects of Bariatric Surgery on Adipokine-Induced Inflammation and Insulin Resistance

Plasma Retinol-Binding Protein 4 (RBP4) Levels and Risk of Coronary Heart Disease

Contact Info

Product

Resources

About